Balyasny Asset Management’s LAVA Medtech Acquisition Corp. Class A Common Stock LVAC Stock Holding History

Balyasny Asset Management’s Portfolio LVAC Stock Details LVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-300,000	Closed	-$3.13M	–	3164
2023 Q1	$3.13M	Sell	300,000 -75,000	-20%	-$776K	0.01%	1269
2022 Q4	$3.85M	Hold	375,000	–	–	0.01%	1138
2022 Q3	$3.77M	Hold	375,000	–	–	0.01%	1160
2022 Q2	$3.73M	Hold	375,000	–	–	0.01%	1072
2022 Q1	$3.74M	Hold	375,000	–	–	0.01%	1076
2021 Q4	$3.75M	Buy	+375,000	New	+$3.71M	0.01%	951

Balyasny Asset Management's LVAC Position: Q2 2023 in Review

Balyasny Asset Management sold out of LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) in Q2 2023, closing a stake of 300,000 shares — an estimated $3.13M sold.

Balyasny Asset Management first reported a position in LVAC in Q4 2021 and held it in 6 quarters. The position peaked at $3.85M in Q4 2022. 0 funds tracked by Wall St. Rank hold LVAC as of Q2 2023.

Balyasny Asset Management reported no remaining LAVA Medtech Acquisition Corp. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Balyasny Asset Management sold 300,000 LAVA Medtech Acquisition Corp. Class A Common Stock shares in Q2 2023, an estimated $3.13M.
Balyasny Asset Management first reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Balyasny Asset Management's LAVA Medtech Acquisition Corp. Class A Common Stock position peaked at $3.85M in Q4 2022.
0 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Class A Common Stock as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.